PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin ® ), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
BioDrugs（2019）
关键词
bevacizumab biosimilar,lung cancer,reference bevacizumab,first-line,non-squamous,non-small-cell,double-blind
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要